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Summary
BRCA1 exerts transcriptional repression through interactionwith CtIP in the C-terminal BRCT domain and ZBRK1 in the cen-
tral domain. A dozen genes, including angiopoietin-1 (ANG1), a secreted angiogenic factor, are corepressed by BRCA1 and
CtIP based on microarray analysis of mammary epithelial cells in 3D culture. BRCA1, CtIP, and ZBRK1 form a complex that
coordinately represses ANG1 expression via a ZBRK1 recognition site in the ANG1 promoter. Impairment of this complex
upregulates ANG1, which stabilizes endothelial cells that form a capillary-like network structure. Consistently, Brca1-defi-
cient mouse mammary tumors exhibit accelerated growth, pronounced vascularization, and overexpressed ANG1. These
results suggest that, besides its role inmaintaining genomic stability, BRCA1 directly regulates the expression of angiogenic
factors to modulate the tumor microenvironment.Introduction
Mutations in the breast cancer susceptibility gene BRCA1 ac-
count for up to 50% of hereditary breast cancer and for almost
all cases of hereditary breast and ovarian cancer syndrome
(Couch et al., 1997; Easton et al., 1993). Also, reduced BRCA1
expression is often correlated with accelerated progression
and growth of sporadic breast cancer (Thompson et al., 1995).
BRCA1 participates in DNA damage repair, cell cycle check-
point control, and transcriptional regulation, serving as a tumor
suppressor to maintain genomic stability. The BRCA1 gene en-
codes a 220 kDa nuclear phosphoprotein of 1863 amino acids
(Chen et al., 1996; Miki et al., 1994), characterized by distinctive
protein-protein interaction surfaces. The N-terminal RING finger
domain dimerizes with BARD1 for ubiquitin ligase activity
(Hashizume et al., 2001), while the C terminus possesses two
tandem copies of the BRCT motif that interact with several cel-
lular proteins, including CtIP (Li et al., 1999; Zheng et al., 2000a).
The central region,mainly encoded by exon 11, contains two nu-
clear localization signals (Chen et al., 1995) and interacts with
a DNA damage repair complex, Rad50/Mre11/NBS1 (Zhong
et al., 1999), and transcription repressor, ZBRK1 (Zheng et al.,
2000b).CANCER CELL 10, 13–24, JULY 2006 ª2006 ELSEVIER INC. DOI 10.101BRCA1 is also involved in developmental and differentiation
processes and exhibits a temporal and spatial expression pat-
tern (Furuta et al., 2005; Lane et al., 1995). Developmental de-
fects and early embryonic death (E6.5) are observed in Brca1
homozygous knockout mice (Hakem et al., 1996; Liu et al.,
1996). BRCA1 facilitates differentiation of mammary epithelia
and is upregulated in rapidly dividing, differentiating cells
(Marquis et al., 1995), whereas its depletion impairs differentia-
tion and promotes cellular proliferation (Furuta et al., 2005). Con-
sistently, in mouse mammary tissue a conditional Brca1 knock-
out displays abnormal ductal morphogenesis and mammary
tumor (Xu et al., 1999).
BRCA1 confers a transcriptional repression on stress-respon-
sive genes p21 andGADD45 through interaction with CtIP at the
C-terminal BRCT domain (aa 1651–1863) (Li et al., 1999, 2001;
Yu et al., 1998). CtIP is an 897 amino acid protein that was
originally identified as a cofactor of CtBP, a C-terminal binding
protein of human adenovirus E1A protein, and is involved in tran-
scriptional repression (Chinnadurai, 2006). CtIP interacts with
different proteins via discrete modules, including a PLDLS motif
(aa 490–494) for CtBP (Schaeper et al., 1998), a region aa 299–345,
phosphorylated at S327, for BRCA1 (Yu and Chen, 2004), and
a LECEE motif (aa 153–157) for retinoblastoma (RB) tumorS I G N I F I C A N C E
BRCA1 plays an essential role in DNAdamage response and cell cycle checkpoint control. Little is knownabout howan impaired func-
tion of BRCA1 is correlated with accelerated growth and progression of hereditary and sporadic breast cancer. We show that BRCA1
forms a repressor complex with CtIP and ZBRK1 at a ZBRK1-responsive element of the angiopoietin-1 promoter in mammary epithelial
cells. A defect of this complex formation derepresses ANG1 transcription, promoting endothelial cell survival and vascular enlarge-
ment in a paracrine fashion. This enhancedangiogenesis contributes to exacerbatedmalignancy of Brca1-deficientmousemammary
tumors. Thus, our study unveils a mechanism for how BRCA1 modulates the tumor microenvironment by transcriptional regulation.6/j.ccr.2006.05.022 13
A R T I C L ETable 1. Genes corepressed by BRCA1 and CtIP in 3D cultured MCF10A cells
Gene symbol Gene name
BRCA1-KD CtIP-KD
fold p value fold p value
ACTR1A ARP1 actin-related protein 1 homolog A, centractin a +2.08 0.048 +2.09 0.047
ANG1* angiopoietin-1 +2.69 0.016 +2.18 0.026
DCP2 decapping enzyme hDcp2 +2.19 0.027 +2.09 0.011
DRLM downregulated in liver malignancy +2.10 0.001 +2.00 0.008
FGF2* fibroblast growth factor 2 (basic; bFGF) +2.03 0.048 +2.04 0.008
HMGA2* high mobility group AT-hook 2 +4.55 0.002 +2.55 0.001
IL1R1 interleukin 1 receptor, type I +2.02 0.004 +2.09 0.001
LIMK1* LIM domain kinase 1 +2.12 0.049 +2.06 0.005
RFC1* replication factor C (activator 1) 1, 145kDa +2.07 0.047 +2.07 0.027
SLC16A4 solute carrier family 16 (monocarboxylic acid transporters), member 4 +2.63 0.002 +2.21 0.037
TA-KRP T cell activation kelch repeat protein +2.17 0.048 +2.17 0.009
*Confirmed by RT-PCR (Figure S1).suppressor (Fusco et al., 1998). Certain tumor-linked mutations
of the BRCT domain abolish CtIP association and prevent
BRCA1-dependent transcriptional repression (Li et al., 1999;
Yu et al., 1998). Moreover, Ctip null mouse embryos die at
E4.0 as blastocysts fail in S phase entry, while the heterozygotes
are short-lived and develop various kinds of tumors that retain
a single wild-type (wt) allele, indicative of haploid insufficiency,
suggesting that Ctip is a bona fide tumor susceptibility gene
(Chen et al., 2005).
Two interacting tumor suppressors, BRCA1 and CtIP, coordi-
nate in certain transcriptional regulatory pathways, namely, DNA
damage response and cell cycle checkpoint control (Li et al.,
1999, 2001). However, it is largely unknown whether they coop-
erate in a transcriptional repression beyond the stress-inducible
pathways. In the present study, we have identified a dozen
genes corepressed by BRCA1 and CtIP in MCF10A mammary
epithelial cells (MECs) in 3D culture using microarray analyses.
Among them,we have examined angiopoietin-1 (ANG1), a factor
secreted to stimulate angiogenesis of neighboring endothelial
cells (Suri et al., 1996), for a BRCA1- and CtIP-dependent tran-
scriptional repression. We demonstrate that BRCA1, CtIP, and
ZBRK1 form a repressor complex at a recognition site of
ZBRK1 in ANG1 promoter, and a defect of this repressor com-
plex formation derepresses ANG1 expression in MECs that pro-
motes survival of the neighboring endothelial cells to form a
capillary-like structure. Consistently, Brca1-deficient mouse
mammary tumors display a high level of Ang1 expression, prom-
inent vascularization, and accelerated growth.
Results
ANG1 expression is corepressed
by BRCA1 and CtIP in MECs
We previously demonstrated that MECs depleted of BRCA1 in
3D matrix, a close mimicry to the in vivo microenvironment,
undergo vigorous proliferation but fail in acinar differentiation
(Furuta et al., 2005), reflecting a phenotype similar to breast
tumorigenesis. Depletion of CtIP evokes a similar phenotype
(unpublished data). To identify the genes that are directly core-
gulated by the two proteins during this process, we performed
microarray analyses on MCF10A cells depleted of BRCA1 or
CtIP by adenoviral RNAi and grown in 3D culture for 15 hr.
Among over a hundred genes with altered expression profiles,
only a dozen were concomitantly upregulated (fold > 2; p < 0.05)14in both sets of experiments (Table 1), suggesting that they are
corepressed by BRCA1 and CtIP. At least five of them, the up-
regulations of which were confirmed by RT-PCR (Figure S1 in
the Supplemental Data available with this article online), are pro-
liferation markers, including ANG1, bFGF, HMGA2, LIMK1, and
RFC1 (Caine et al., 2003; Cullmann et al., 1995; Davila et al.,
2003; Imura et al., 2004; Tessari et al., 2003). We were particu-
larly intrigued by ANG1, a secreted angiogenic factor modulat-
ing the tumor microenvironment. ANG1 promotes tubular for-
mation and survival of endothelial cells and enhances blood
vessel growth and maturation upon binding to Tie2 receptor ty-
rosine kinase on the endothelial cell surface (Hayes et al., 1999;
Kwak et al., 1999; Suri et al., 1996). Dysfunction of BRCA1 is cor-
related with accelerated growth and progression of breast
tumors (Stoppa-Lyonnet et al., 2000; Xu et al., 1999), often dis-
playing microvascular proliferation (Goffin et al., 2003). Consis-
tently, we observed that Brca1-deficient mouse mammary
tumors exhibit pronounced growth and extensive enlargement
of vasculature (Table 2).
To verify our microarray data showing that a decrease of
BRCA1 (27.9-fold) or CtIP (23.9-fold) in MCF10A cells evoked
a significant increase of ANG1 (+2.7- or +2.4-fold, respectively)
(Figures 1A and 1B), we performed RT-PCR on MCF10A cells in
3D culture. Reduced expression of BRCA1 or CtIP paralleled
increased ANG1 expression (Figures 1C and 1D), suggesting
that a deficiency of either BRCA1 or CtIP upregulates ANG1
expression.
The interaction between BRCA1 and CtIP is required
for transcriptional repression of the ANG1 promoter
BRCA1 and CtIP both serve as transcriptional corepressors and
interact with each other. To determine a potential transcriptional
regulation of ANG1 by BRCA1 and CtIP, we measured the lucif-
erase reporter activity of ANG1 promoter constructs with differ-
ent lengths (Figure 2A) after BRCA1 or CtIP was depleted in
MCF10A cells by adenoviral RNAi. Only construct C, encoding
a 3 kb full-length ANG1 promoter, showed a significant increase
in the activity as BRCA1 level decreased by increasing adenovi-
ral RNAi (Figures 2B and 2C), suggesting that the region 23040
to 21799 is essential for transcriptional repression by BRCA1.
Similar results were obtained in both 2D monolayer and 3D cul-
tures, independent of the experimental systems. Likewise, as
CtIP was depleted by adenoviral RNAi, construct C showed
a comparable increase in the activity (Figure 2D). These resultsCANCER CELL JULY 2006
A R T I C L Eimply that the region (23040/21799) of ANG1 promoter is sub-
ject to corepression by BRCA1 and CtIP.
To test if the interaction of BRCA1 and CtIP is required for
ANG1 repression, we generated RNAi-resistant BRCA1 and
CtIP expression plasmids that are either wild-type or point
mutants: C61G (RING domain), Q356R (central region), and
M1775R (BRCT domain) for BRCA1; and S327A for CtIP. A mu-
tation of BRCA1 at M1775R impairs binding of a group of BRCT
domain-interacting proteins including CtIP, whereas a mutation
of CtIP at S327A impedes BRCA1 binding (Yu and Chen, 2004;
Yu et al., 1998). Treatment of MCF10A cells with an RNAi-resis-
tant BRCA1 (Figure 2E) or CtIP (Figure 2F) plasmid prior to the
cognate adenoviral RNAi infection effectively rescued their
expressions. As the luciferase activity of construct C was mea-
sured under this context (Figure 2G), cells expressing RNAi-
resistant wild-type BRCA1 or CtIP endured the repression
despite the increasing adenoviral RNAi. In contrast, cells ex-
pressing RNAi-resistant BRCA1M1775R or CtIPS327A mutant
Table 2. Blood vessel area of p53D5–6/D5–6 and Brca1D11/D11;p53D5–6/D5–6
mouse mammary tumors
Genotype Mouse ID
Tumor
vol.a (ml)
Latency
(months)
Blood vessel
luminal
areab (mm2)
p53D5–6/D5–6 (n = 14)
9108 1.767 16.5 93.0 (658.6)
9128 0.666 18.0 84.5 (655.8)
9133 0.762 16.5 66.2 (639.4)
9207 0.635 15.0 62.4 (632.1)
[9268] 0.831 21.2 41.0 (615.6)
9270 0.831 16.4 49.8 (615.8)
9288 0.606 17.3 59.4 (628.2)
9311 0.697 19.2 69.1 (631.1)
9323 0.762 16.2 94.0 (654.8)
9326 0.762 17.1 90.0 (640.3)
9339 1.888 21.4 164.4 (688.9)
[9342] 2.145 21.5 141.2 (695.5)
[9345] 2.145 20.5 79.5 (660.1)
[9349] 0.635 19.0 64.1 (636.2)
mean 1.072 18.3 82.8*
SD 60.588 62.2 633.9
Brca1D11/D11;p53D5–6/D5–6 (n = 17)
[741] 1.767 3.9 329.8 (6209.2)
806 0.831 8.2 161.3 (681.2)
[820] 2.424 6.5 313.4 (6226.4)
[824] 1.337 6.2 310.8 (675.1)
847 0.831 6.4 160.3 (639.9)
876 0.762 6.4 381.2 (6131.6)
[905] 0.905 6.9 139.4 (695.1)
913 1.437 6.9 157.6 (676.3)
942 0.905 7.1 90.3 (621.7)
945 1.064 6.5 111.2 (638.4)
947 0.905 3.4 206.7 (690.5)
960 0.697 5.9 126.0 (664.5)
986 0.762 4.9 182.4 (663.7)
1043 0.831 4.4 582.3 (6309.1)
1094 0.697 6.8 102.2 (641.3)
1114 0.831 6.9 95.4 (643.6)
1133 0.762 6.4 361.0 (632.6)
mean 0.996 6.1 224.2*
SD 60.460 61.3 6135.0
Tumor samples used for photographic display (Figure 6) are indicated in
brackets. *p = 0.000672.
aTumor volume = p/6 [(L + W + D)/3]3.
bAverage luminal area of blood vessels (n = 400–600) for each tumor sample
(6SD).CANCER CELL JULY 2006failed to repress the activity even at the lowest dose (5 MOI) of
adenoviral infection, suggesting that the interaction of BRCA1
and CtIP is essential for repressing ANG1 transcription. Interest-
ingly, BRCA1Q356R mutant, but not BRCA1C61G mutant, also
failed to repress ANG1 transcription, indicating that the central
region of BRCA1 is also involved in this process.
A single ZBRK1 recognition site in ANG1 promoter
mediates BRCA1 and CtIP corepression
BRCA1 interacts at the central region (aa 341–748) with ZBRK1,
which mediates BRCA1-dependent transcriptional repression
of certain genes by directly binding to a consensus motif
(GGGxxxCAGxxxTTT) (Zheng et al., 2000b). If a ZBRK1 recogni-
tion site is indeed present inANG1 promoter, a chimeric transac-
tivator, a ZBRK1 DNA binding domain fused to a VP16 transacti-
vation domain, would recognize this sequence and upregulate
the ANG1 promoter activity (Zheng et al., 2000b). As shown in
Figure 3A, the presence of this chimeric ZBRK1 promoted the lu-
ciferase reporter activityof constructC,butnotAorB, suggesting
that the region23040 to21799 contains potential ZBRK1 recog-
nition sites involved in transcriptional repression of ANG1 by
ZBRK1. Sequence analyses revealed that this region contains
a total of five potential ZBRK1 binding sites. To map a functional
ZBRK1 binding site, we generated deletion mutants in the first
three ZBRK1 binding sites (C1: D22600/22200), the last two
sites (C2: D22200/21800), and all the five sites (C3: D22600/
21800) (Figure 3B). Reporter assays showed that C1 and C3,
but not C2, were repression defective, and neither BRCA1
(Figure 3C) nor CtIP depletion (Figure 3D) further derepressed
the activities. Sequence analysis of the first three potential sites
revealed a nearly canonical ZBRK1 consensus motif (22310/
22296: GAGxxxCAGxxxTTT). We then generated a mutant con-
struct, C-mt-Z, by substituting the five essential nucleotides
(GTTxxTTTGxxxTTT) (Figure 3B) and found that this mutant
Figure 1. ANG1 is corepressed by BRCA1 and CtIP in MCF10A cells
A: Microarray data of relative expression levels of BRCA1 and ANG1 in
MCF10A cells infected with adenoviral BRCA1- versus luciferase-RNAi at 20
MOI for 24 hr and grown in 3D culture for 15 hr.
B: Microarray data of relative expression levels of CtIP and ANG1 in MCF10A
cells infected with adenoviral CtIP- versus luciferase-RNAi at 20 MOI for 24 hr
and grown in 3D culture for 15 hr.
C: RT-PCR analysis on BRCA1 and ANG1 expressions in MCF10A cells in-
fected with adenoviral luciferase- or BRCA1-RNAi for 24 hr and grown in
3D culture for 15 hr. a-tubulin (a-TUB) serves as a loading control.
D: RT-PCR analysis on CtIP and ANG1 expressions in MCF10A cells infected
with adenoviral luciferase- or CtIP-RNAi for 24 hr and grown in 3D culture
for 15 hr. a-tubulin serves as a loading control.15
A R T I C L EFigure 2. Interaction of BRCA1 and CtIP is required for transcriptional repression of ANG1 promoter
A: Schematics of ANG1 reporter constructs A–C in the promoter region. A, 2821/+199; B, 21799/+199; and C, 23040/+199 from the start codon.
B: Relative luciferase activity of reporter constructs A–C in MCF10A cells infected with adenoviral BRCA1-RNAi for 24 hr in 2D monolayer culture. Error bar,6SD.
C: Relative luciferase activity of reporter constructs A–C in MCF10A cells infected with adenoviral BRCA1-RNAi for 24 hr in 3D culture. Error bar, 6SD.
D: Relative luciferase activity of reporter constructs A–C in MCF10A cells infected with adenoviral CtIP-RNAi for 24 hr in 2D monolayer culture. Error bar, 6SD.
E: Western analysis on the expression of BRCA1 (wt, C61G, Q356R, or M1775R) after treatment with an RNAi-resistant (RM) construct prior to adenoviral BRCA1-
RNAi infection. p84 serves as a loading control.
F:Western analysis on the expression of GFP-CtIP (wt or S327A) after treatment with an RNAi-resistant (RM) construct prior to adenoviral CtIP-RNAi infection. p84
serves as a loading control.
G: Relative luciferase activity of reporter construct C in MCF10A cells treated with an RNAi-resistant BRCA1 (wt, C61G, Q356R, or M1775R) or CtIP (wt or S327A)
prior to the cognate adenoviral RNAi infection (BR, BRCA1; CT, CtIP). Error bar, 6SD.responded to repression by neither BRCA1 (Figure 3C), CtIP (Fig-
ure 3D), nor ZBRK1 (Figure 3A), suggesting that this putative site
(22310/22296) is a strong candidate for a ZBRK1 binding site.
To test whether ZBRK1 directly binds to this putative site,
a 33-mer radiolabeled oligonucleotide probe (22319/22287)
harboring the ZBRK1 recognition site (22310/22296) of ANG1
promoter (wt-Z) was used to perform an electromobility shift
assay (EMSA) using either GST-fused ZBRK1 eight-Zn finger
domain (Zheng et al., 2000b) or nuclear extract. We included
a nonlabeled wt (wt-Z) or point mutant ZBRK1 (mt-Z) binding se-
quence of ANG1 promoter and AP12, a canonical consensus16ZBRK1 binding sequence (Zheng et al., 2000b), for competition
experiments. As expected, a nonlabeled wild-type ANG1 or
AP12 competitor, but not mutant ANG1, competed with a
labeled wild-type probe for binding ZBRK1, suggesting that
ZBRK1 directly binds to this site (22310/22296) (Figure 3E).
To further demonstrate that this ZBRK1 recognition site is func-
tional in vivo, we generated a heterologous reporter construct
with a 800 bp fragment (22600/21800) containing a wild-type
(3P-26-wt-Z) or mutant (3P-26-wt-Z) ZBRK1 binding site
(22310/22296) (Figure 3F). Reporter assay showed that the
activity increased as ZBRK1 level decreased by increasingCANCER CELL JULY 2006
A R T I C L EFigure 3. BRCA1, CtIP, and ZBRK1 corepress ANG1 expression via a single ZBRK1 recognition element in the promoter
A: Relative luciferase activity of ANG1 reporter constructs A–C and C-mt-Z, a point mutant in a putative ZBRK1 binding site (22310/22296), in MCF10A cells
expressing a chimeric (CM) ZBRK1 where the KRAB repression domain is replaced with the VP16 activation domain. Error bar, 6SD.
B: Schematics of ANG1 reporter constructs derived from construct C. C-wt, wild-type (23040/+199) containing five potential ZBRK1 binding sites; C-mt-Z,
a point mutant in a putative ZBRK1 binding site (22310/22296); C1, a deletion of the first three binding sites (D22600/22200); C2, a deletion of the last two
binding sites (D21200/21800); and C3, a deletion of all the five binding sites (D22600/21800).
C: Relative luciferase activity of reporter construct C derivatives in MCF10A cells after infection with adenoviral BRCA1-RNAi for 24 hr. Error bar, 6SD.
D: Relative luciferase activity of reporter construct C derivatives in MCF10A cells after infection with adenoviral CtIP-RNAi for 24 hr. Error bar, 6SD.
E: EMSA on a competition between a radiolabeled wild-type ZBRK1 site (22310/22296) in ANG1 promoter (wt-Z, 33 mer) and a nonlabeled competitor for
binding GST-ZBRK1-Zn protein (the eight-zinc finger domain) or ZBRK1 in nuclear extract (NE). The competitors used are wild-type (wt-Z) or a point mutant
(mt-Z) of a ZBRK1 site (22310/22296) in ANG1 promoter (33 mer) and a canonical ZBRK1 binding sequence (AP12, 29 mer).
F: (Top) Relative luciferase activity of a regulatory region (22600/21800) in ANG1 promoter with a wild-type (3P-26-wt-Z) or point mutant (3P-26-wt-Z) of a pu-
tative ZBRK1 binding site (22310/22296) in MCF10A cells after infection with adenoviral ZBRK1-RNAi for 24 hr. Error bar, 6SD. (Bottom) Schematics of ANG1
reporter constructs used. 3P-26-wt-Z, a fragment composed of a regulatory region; and 3P-26-mt-Z, a fragment of a regulatory region with point mutations
in a ZBRK1 binding site.adenoviral ZBRK1 RNAi (see below Figure 4A), whereas a mu-
tant ZBRK1 site was repression defective (Figure 3F), further
confirming that this site is an authentic ZBRK1 recognition site.
ZBRK1, BRCA1, and CtIP form a repressor
complex on ANG1 promoter
Since BRCA1/CtIP corepresses ANG1 promoter via a ZBRK1
recognition site, it is expected that depletion of ZBRK1 wouldCANCER CELL JULY 2006derepress ANG1 expression, similar to the effect of BRCA1
and CtIP depletion (Figure 1A). To test this possibility, we de-
pleted ZBRK1 by adenoviral mediated RNAi in MCF10A cells
in 3D culture and assessed the ANG1 expression level using
RT-PCR. Reduced ZBRK1 expression paralleled increased
ANG1 expression (Figure 4A), suggesting that a deficiency of
ZBRK1 upregulates ANG1 repression. These results altogether
implicate that ZBRK1, BRCA1, and CtIP coordinately repress17
A R T I C L EFigure 4. ZBRK1, BRCA1, and CtIP form a repres-
sor complex on ANG1 promoter
A: RT-PCR analysis on ZBRK1 and ANG1 expres-
sions in MCF10A cells infected with adenoviral
luciferase- or ZBRK1-RNAi for 24 hr and grown in
3D culture for 15 hr. b-actin serves as a loading
control.
B: Reciprocal coimmunoprecipitation of CtIP,
BRCA1, and ZBRK1 from nuclear extract.
C: DNA immunoprecipitation by antibodies
against ZBRK1, BRCA1, and CtIP from nuclear
extract mixed with an oligonucleotide probe
encompassing a ZBRK1 binding sequence
(wt-Z, mt-Z, or AP12).
D: ChIP analysis on a 300 bp fragment around
a ZBRK1 binding site in ANG1 promoter (22400/
22100) to detect the association of BRCA1,
CtIP, and ZBRK1 in MCF10A cells infected with
adenoviral luciferase-, BRCA1-, CtIP-, or ZBRK1-
RNAi at 20 MOI for 24 hr.ANG1 expression. Since BRCA1 binds CtIP via its BRCT domain
(Li et al., 1999) and ZBRK1 via its central domain (Zheng et al.,
2000b), it is likely that these three proteins form a repressor
complex on the ZBRK1 recognition site. To test this possibility,
these three proteins were reciprocally coimmunoprecipitated
from nuclear extract (Figure 4B), suggesting that they form
a complex. Next, wemixed a radiolabeled oligonucleotide probe
containing a wild-type (wt-Z or AP12) or mutant (mt-Z) ZBRK1
binding sequence with nuclear extract for immunoprecipitation.
Antibodies against ZBRK1, BRCA1, and CtIP brought down
a wild-type (wt-Z or AP12), but not mutant (mt-Z), oligonucleo-
tide specifically (Figure 4C). Finally, to demonstrate that this
complex is associated with ANG1 promoter in vivo, we per-
formed a chromatin immunoprecipitation (ChIP) assay on a
300 bp fragment around the ZBRK1 site (22400/22100). As
shown in Figure 4D, ZBRK1, BRCA1, and CtIP colocalized on
ANG1 promoter, while an individual depletion of either protein
by RNAi completely abolished the association of all the three
proteins with the promoter, suggesting that the three partici-
pants are all essential for the complex formation. Taken to-
gether, these data substantiate a notion that BRCA1, CtIP,
and ZBRK1 coordinately form a repressor complex tethered at
the ZBRK1 recognition site in ANG1 promoter.
Expression of ANG1 from MECs is essential for the
stability of capillary-like network structures formed
by neighboring endothelial cells in 3D matrix
To assess a biological consequence of derepressed ANG1 ex-
pression, we coculturedMCF10A cells with human umbilical en-
dothelial cells (HUVECs) in 3D matrix. HUVECs alone formed
a thin layer of capillary-like network structure in a day but
soon came to disintegrate and died in a week under this exper-
imental condition (Figure 5Ba). When HUVECs were cocultured
with luciferase-RNAi/GFP-treated MCF10A cells, they formed
a well-defined thin layer of capillary-like structure in a day; how-
ever, the endothelial cells, indicated as nonfluorescent cells,
started to die in 3 days, and the capillary-like structure dis-
integrated in a week (Figure 5Bb). When HUVECs unlabeled
(Figure 5Be) or labeled with histone H2B/GFP (Figure 5Bf)
were cocultured with MCF10A/ANG1 cells that stably express
ANG1by retroviral infection (Figure 5A), they formed a thick layer18of capillary-like structure, which sustained over a week. When
HUVECs were cocultured with MCF10A cells infected with
BRCA1-RNAi/GFP (Figure 5Bc) or CtIP-RNAi/GFP (Figure 5Bd)
adenovirus, they formed a thick layer of capillary-like structure,
which maintained for a week in a manner similar to those cocul-
tured with MCF10A/ANG1 cells. To validate the essential role of
ANG1 in the survival of cocultured endothelial cells, we treated
MCF10A cells with ANG1 siRNA, which was shown by Western
analysis to completely deplete ANG1 in MCF10A/ANG1 cells
after 36 hr (Figure 5C). HUVECs cocultured with ANG1 siRNA-
treated MCF10A/ANG1 cells formed a thin layer of capillary-
like structure in a day but soon came to disintegrate and died
after a week (Figure 5Dh) in a manner similar to those cocultured
with Luc-RNAi/GFP-infected MCF10A cells (Figures 5Da and
5Db). Likewise, when HUVECs were cocultured with MCF10A
cells treated with ANG1 siRNA prior to BRCA1-RNAi/GFP
(Figure 5Dd) or CtIP-RNAi/GFP (Figure 5Df) adenoviral infection,
they formed a thin layer of capillary-like structure in a day, but
the endothelial cells, indicated as nonfluorescent cells, started
to disintegrate after 3 days and died in a week, leaving aggre-
gates of fluorescent MECs. Based on these observations, upre-
gulated expression of ANG1 from MECs, either by the over-
expression construct or by depletion of BRCA1 or CtIP, is
essential for the stability of capillary-like structures formed by
the cocultured endothelial cells in 3D matrix.
Brca1-deficient mouse mammary tumors exhibit an
accelerated growth and harbor enlarged blood
vessels along with upregulated Ang1 expression
To test if these in vitro observations gain support from animal
studies, we examined mammary tumor samples from Brca1-
deficient mice. BRCA1-associated tumorigenesis is often linked
to a loss of p53 (Xu et al., 1999). To recapitulate the BRCA1-
related tumor pathogenesis, we used a mouse model inacti-
vated in both Brca1 and p53 genes (Brca1D11/D11;p53D5–6/D5–6)
(n = 17) in comparison to mice inactivated only in p53 gene
(p53D5–6/D5–6) (n = 14) as a control (Lin et al., 2004; Xu et al.,
1999). Brca1-deficient tumors exhibited a substantially shorter
latency than control tumors (6.16 1.3 versus 18.36 2.2months)
to reach a comparable size (0.9966 0.460 versus 1.0726 0.588
ml, respectively) (Table 2). In general, Brca1-deficient tumorsCANCER CELL JULY 2006
A R T I C L EFigure 5. Expression of ANG1 from MECs is essential for the survival of HUVECs and stability of the capillary-like structure in 3D matrix
A: Western analysis of ANG1 expression in MCF10A/ANG1 cells in comparison to the parental MCF10A cells.
B: Survival of HUVECs and stability of the capillary-like structure in 3D matrix. Images were captured with Phase I/FITC reflector at 1003 magnification. Ba:
HUVECs only. Bb: HUVECs cocultured with adenoviral luciferase-RNAi/GFP-infected MCF10A cells. Bc: HUVECs cocultured with adenoviral BRCA1-RNAi/
GFP-infected MCF10A cells. Bd: HUVECs cocultured with adenoviral CtIP-RNAi/GFP-infected MCF10A cells. Be: HUVECs cocultured with MCF10A/ANG1 cells.
Bf:HUVECs marked with histone H2B/GFP and cocultured with MCF10A/ANG1 cells. (1) 24 hr, (2) 3 days, and (3) 7 days of growth in 3D culture. Adenoviral RNAi
infection was performed at 20 MOI for 24 hr. Scale bar, 50 mm.
C: Western analysis on ANG1 expression in MCF10A/ANG1 cells treated with luciferase or ANG1 siRNA for a different period of time.
D: Pretreatment of MCF10A cells with ANG1 siRNA destabilizes the capillary-like structure formed by HUVECs in 3D matrix. Images were captured with Phase I/
FITC reflector at 1003magnification. Da and Db: HUVECs cocultured with MCF10A cells pretreated with luciferase (Da) or ANG1 (Db) siRNA prior to adenoviral
luciferase-RNAi/GFP infection at 20 MOI for 24 hr.DcandDd:MCF10A cells pretreated with luciferase (Dc) or ANG1 (Dd) siRNA prior to adenoviral BRCA1-RNAi/
GFP infection at 20 MOI for 24 hr. De and Df: MCF10A cells pretreated with luciferase (De) or ANG1 (Df) siRNA prior to adenoviral CtIP-RNAi/GFP infection at 20
MOI for 24 hr.DgandDh:HUVECs cocultured with MCF10A/ANG1 cells pretreated with luciferase (Dg) or ANG1 (Dh) siRNA. (1) 24 hr, (2) 3 days, and (3) 7 days of
growth in 3D culture. Adenoviral RNAi infection was performed at 20 MOI for 24 hr. Scale bar, 50 mm.displayed an ensanguined appearance, noticeably distinct from
control tumors with the same size (Figure 6A). To examine the
blood vessel status of these tumor specimens, they were
stained against CD31, an endothelial cell marker (Machein
et al., 2004). Apparently, Brca1-deficient tumors contained
larger blood vessels compared to control tumors (Figures 6B
and 6C). The blood vessel luminal area of Brca1-deficient tumor
was almost three times the size of that of the control tumor
(224.2 6 135.0 versus 82.8 6 33.9 mm2; p < 0.001) (Table 2),
while microvascular density (mm2) did not significantly differ be-
tween the two sets of tumors (p = 0.22; data not shown), consis-
tent with a finding that ANG1 causes vessel enlargement without
angiogenic sprouting during development (Thurston et al.,
2005). Interestingly, analogous regulatory elements, includingCANCER CELL JULY 2006a ZBRK1 recognition site, were found in the mouse Ang1 pro-
moter region (Figure 6D), suggesting that mouse Ang1 expres-
sionmay be subjected to a similar mode of regulation as human.
Consistently, Ang1 expression was mostly upregulated in
Brca1-deficient tumors, but not in control tumors (Figure 6E).
Taken together, these results support a notion that inactivation
of BRCA1 in MECs upregulates ANG1 expression to support
formation of large blood vessels.
Discussion
BRCA1 plays an essential role in DNAdamage response and cell
cycle checkpoint control, which are intimately linked to a re-
straint of cancer initiation. Additional functions of BRCA1 remain19
A R T I C L EFigure 6. Brca1-deficient mouse mammary tu-
mors exhibit enlarged blood vessels and overex-
pressed ANG1
A: Whole mammary tumors (w1.8 cm in diame-
ter) excised from p53D5–6/D5–6 (Aa) and
Brca1D11/D11;p53D5–6/D5–6 (Ab) mice.
B: Mammary tumor sections from p53D5–6/D5–6
mice stained for CD31 (brown) and counter-
stained with hematoxylin. Mouse ID: 9268 (Ba),
9342 (Bb), 9345 (Bc), and 9349 (Bd). Images
were captured at 2003 (1) and at 10003 (2)
magnifications. Scale bar, 50 mm.
C: Mammary tumor sections from Brca1D11/D11;
p53D5–6/D5–6 mice stained for CD31 (brown) and
counterstained with hematoxylin. Mouse ID: 741
(Ca), 820 (Cb), 824 (Cc), and 905 (Cd). Images
were captured at 2003 (1) and at 10003 (2)
magnifications. Scale bar, 50 mm.
D: ANG1 promoter region in human (Da) and
mouse (Db) around a ZBRK1 binding site with
conserved transcriptional regulatory elements.
AML-1, acute myeloid leukemia protein-1; AP-1,
activator protein-1; ETS-1, v-ets erythroblastosis
virus E26 oncogene homolog 1; IK-1/2, Ikaros
1/2; NF-kB, nuclear factor kappa B.
E: Ang1 expression in p53D5–6/D5–6 and Brca1D11/D11;
p53D5–6/D5–6 mouse mammary tumors detected
by RT-PCR. GAPDH serves as an internal control.
F: A schematic for ANG1 transcriptional repres-
sion by BRCA1, CtIP, and ZBRK1 via a ZBRK1
recognition site in the promoter.to be further characterized. In this communication, we reveal
that BRCA1, in coordination with CtIP and ZBRK1, exerts a tran-
scriptional repression on ANG1 that pertains to cancer progres-
sion. To mimic in vivo conditions, we depleted BRCA1 and CtIP
in normal MECs cultured in extracellular matrix. Microarray anal-
yses identified a dozen genes corepressed by BRCA1 and CtIP.
We focused onANG1 since it may participate in cancer progres-
sion through angiogenesis. Our results demonstrated that
BRCA1 and CtIP, along with ZBRK1, form a repressor complex
on ANG1 promoter via a ZBRK1 recognition element (Figure 6F)
and thatBrca1-deficient mousemammary tumors exhibit prom-
inent vascularization and accelerated growth along with Ang1
upregulation. This suggests that derepressed ANG1 expression
in MECs in the absence of BRCA1 is a pathogenic drive for
neoplastic growth.
Depletion of BRCA1 impairs acinar differentiation but pro-
motes proliferation of MECs into a tumor-like aggregate in 3D
culture (Furuta et al., 2005). Strikingly, our preliminary results
showed that depletion of CtIP as well as ZBRK1 leads to
a phenotype identical to BRCA1 depletion, suggesting that20they share at least one common regulation pathway. ZBRK1,
a sequence-specific transcriptional repressor that binds to the
canonical GGGxxxCAGxxxTTT motif, interacts with the central
region of BRCA1 (aa 341–748) and mediates the transcriptional
repression activity of BRCA1 (Zheng et al., 2000b). Interestingly,
there are five potential ZBRK1 sites inANG1 promoter due to the
degeneracy of the consensus motif, but only one site (nt22310/
22296) has the in cis transcriptional repression function, since
point mutations at this site abolished the capacity (Figure 3).
Through this recognition site, ZBRK1, BRCA1, and CtIP form
a repressor complex on ANG1 promoter. This conclusion was
supported by the following observations. First, a defect in
BRCA1, CtIP, and ZBRK1 complex formation on ANG1 pro-
moter, caused by lacking one of the participants or their interac-
tions, impairs ANG1 transcriptional repression. Second,
BRCA1, CtIP, and ZBRK1 can be coimmunoprecipitated with
an oligonucleotide containing the wild-type ZBRK1 recognition
sequence. Third, by ChIP analysis, BRCA1, CtIP, and ZBRK1
colocalized at ANG1 promoter. It is noted that depletion of
one of these three components leads to disassembly of theCANCER CELL JULY 2006
A R T I C L Eentire repressor complex including ZBRK1, suggesting that the
stability of ZBRK1 binding to the recognition site depends on the
integrity of the complex. This is inconsistent with the result from
an in vitro binding assay showing that ZBRK1 alone binds to its
consensus sequence. How to reconcile this discrepancy re-
mains unclear. Nevertheless, BRCA1 was shown to facilitate
ZBRK1 binding to the recognition site in vivo (Tan et al., 2004),
and CtIP is also likely to contribute in a similar manner, although
the precise architecture of this complex binding to ZBRK1 site
remains to be elucidated.
Apparently, the regulation of ANG1 promoter would be more
complicated than that by a repressor complex alone. Since
a point mutation in the ZBRK1 binding site (22310/22296) as
well as a deletion in the surrounding region (D22600/21800) up-
regulated ANG1 transcription (Figure 3), the region 22310 to
22296 must be involved in repression, while the region outside
(23040/22600) must be involved in activation once the repres-
sion is removed. It is probable that derepression of ANG1 in the
region 22310/22296 evokes a subsequent activation of the
neighboring region by altering the local chromatin structure to
allow the accessibility to certain transactivators. In fact, the re-
gion around the ZBRK1 binding site in ANG1 promoter encom-
passes various conserved transcriptional regulatory elements,
such as AML1 (CBF-a/CBFA2) (Figure 6D), which is responsible
for upregulation of ANG1 expression during embryogenesis
(Brown et al., 2004; Takakura et al., 2000). Clearly, derepression
is the first step for full activation of the promoter. The mecha-
nisms of how the repressor complex is removed from the
ZBRK1 site and how these two steps are coordinated in regulat-
ing ANG1 promoter warrant further investigation.
Angiogenesis is a critical process for tumor progression.
ANG1 promotes tubular formation and survival of endothelial
cells (Hayes et al., 1999; Kwak et al., 1999) and enhances blood
vessel growth andmaturation (Suri et al., 1996). Consistently, we
observed that ANG1 expressed from MECs exerts a paracrine
action on neighboring endothelial cells for their survival and
stability of capillary-like network structures. Brca1D11/D11;
p53D5–6/D5–6mousemammary tumors, characterizedby their ac-
celerated growth and ensanguined appearance, harbor promi-
nently enlarged blood vessels compared to p53D5–6/D5–6 mouse
mammary tumors. Such a phenotype of Brca1-deficient mam-
mary tumorsmaybeattributed toderepressedANG1expression
from MECs, stabilizing the adjacent blood vessels and promot-
ing their growth to provide conduits for supplying nutrition as
well as removing waste, consistent with the observation that
ANG1 causes vessel enlargement without angiogenic sprouting
during development (Thurston et al., 2005). Furthermore, glio-
mas overexpressing ANG1 exhibit accelerated tumor growth
and extensive vasculature (Machein et al., 2004), a phenotype
similar to Brca1D11/D11;p53D5–6/D5–6 mouse mammary tumors.
Although it is yet tobeexaminedwhetherBRCA1-associatedhu-
manbreast tumors harbor enlargedblood vessels as observed in
mice, these tumors metastasize to a distant site through the
bloodstream instead of lymphatic routes (Foulkes et al., 2003),
suggesting that they develop blood vessels much earlier than
non-BRCA1-associated tumors. Our observation in mice pro-
vides a likely explanation of this clinical manifestation.
In addition to ANG1, one of the identified genes bFGF is also
involved in angiogenesis (Imura et al., 2004), while several other
genes, HMGA2, LIMK1, and RFC1, are involved in proliferation
(Cullmann et al., 1995; Davila et al., 2003; Tessari et al., 2003).CANCER CELL JULY 2006As the net effect, an impaired transcriptional repression activity
of BRCA1 and CtIP will promote angiogenic and proliferative
potentials of cells. Currently, we are examining if the remaining
genes are regulated under a similar mechanism as ANG1,
aiming to further understand the cellular events involved in the
progression of BRCA1- and CtIP-associated tumors.
A neoplastic potential due to a dysfunction of BRCA1 tumor
suppressor has been largely ascribed to the genomic instability
resulting from defects in DNA damage-responsive pathways.
However, the present study shows that BRCA1 deficiency mod-
ulates the tissue microenvironment by derepression of ANG1 (or
bFGF) that promotes the growth of adjacent vasculature in
a paracrine fashion to nourish a neoplasm. Moreover, an aber-
rant activity of a BRCA1-interacting partner, CtIP tumor sup-
pressor, also deregulates ANG1 expression, whichmay likewise
pertain to the etiology of tumor growth in Ctip heterozygous
mice (Chen et al., 2005). Apparently, these two tumor suppres-
sors have much broader activities than other tumor susceptibil-
ity genes, such as MSH2 and ATM, which exclusively play roles
in guarding genomic stability. This study concludes that BRCA1
and CtIP possess an additional role in tumor suppression, via
a ZBRK1 element, by regulating the intercellular signaling within
the tissue microenvironment besides maintaining the genomic
stability within the cell. This viewwill extend their tumor suppres-
sion functions to the surroundings that influence the fate of
neighboring cells and fortify the pathogenic relevance of their
defect to neoplastic growth.
Experimental procedures
Cell cultures
Human mammary epithelial MCF10A cells and umbilical endothelial cells
(HUVECs) were cultured as described (Debnath et al., 2003; Shekhar et al.,
2000), respectively.
Adenoviral RNAi construction
The adenovirus-based RNAi vector was generated by cloning an expression
cassette of U6 promoter-BRCA1, -CtIP, or -ZBRK1 short hairpin RNAi (0.4
kb) into pAdTrack plasmid upstream of a CMV-GFP cassette (1.6 kb) (He
et al., 1998; Sui et al., 2002). The target sequences are as follows: BRCA1,
50-GGCTACAGAAACCGTGCCAAA-30; CtIP, 50-GGGAGCAGACCTTTCT
CAGTA-30; and ZBRK1, 50-AAACCATGTCATGAACATGAT-30. Adnoviruses
were produced as described (Furuta et al., 2005). MCF10A cells seeded at
5 3 105 cells/60 mm plate were infected with adenovirus at a designated
MOI for 24 hr.
RNAi-resistant BRCA1 and CtIP plasmids
TheRNAi-targeted nucleotide sequence in a full-lengthBRCA1 cDNA, the ex-
pression of which was driven by a CMV promoter in CHpL vector (Li et al.,
1999), was partially substituted without affecting the amino acid residues
(50-GGCTACCGGAATAGGGCCAAA-30), and a cancer-linked point mutation
of BRCA1 at C61G, Q356R, or M1775R was introduced into the wild-type
RNAi-resistant construct using a site-directed mutagenesis kit (Stratagene).
Similarly, the RNAi-targeted nucleotide sequence in GFP-CtIP construct,
containing a full-length CtIP cDNA N-terminally fused to GFP (Li et al.,
2001), was partially substituted as follows: 50-GGGAGCTGACTTGTCTC
AGTA-30, and a point mutation of CtIP at S327A was introduced into the
wild-type RNAi-resistant construct. Correct substitutions were confirmed
by sequencing. Respective primer sequences used are shown in Table S1.
MCF10A cells seeded at 5 3 105 cells/60 mm plate were transfected with 3
mg of RNAi-resistant construct using Fugene6 (Roche) prior to adenoviral
RNAi infection.
Microarray and RT-PCR
MCF10A cells seeded at 5 3 105 cells/60 mm plate were infected with ade-
noviral luciferase-, BRCA1-, CtIP-, or ZBRK1-RNAi in duplicate at 20 MOI for21
A R T I C L E24 hr. Infected cells were reseeded at 5 3 105 cells in a 60 mm plate pre-
coated with Growth Factor Reduced Matrigel (BD Biosciences) and covered
with the growth medium containing 2% Matrigel at 37ºC for 15 hr. RNA was
extracted from these cells with Trizol (Invitrogen), clarified by RNeasy spin
column (Quiagen), and quality assessed. cDNA synthesized from the
harvested RNA using SuperScript Double-Stranded cDNA Synthesis Kit
(Invitrogen) served as a template for PCR amplification with respective
primers (Table S1), and a portion of it was biotin-labeled using GeneChip
IVT Labeling Kit (Affymetrix), hybridized onto Affymetrix HG U133 PLUS 2.0
array (54,676 genes), and stained with streptavidin-phycoerythrin. The hy-
bridized array was analyzed using GeneChip Scanner 3000 and GCOS 1.2
software (Affymetrix) for multiplex pairwise comparison at the UCIMicroarray
Core service. The statistical significance was evaluated by ANOVA single
factor analysis using MS Excel XP, and the fold difference > 2 as well as p
value < 0.05 was considered significant. Microarray data are available at
Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) with
the following accession numbers: BRCA1-KD (GSM106933, GSM106968)
versus Luc-KD (GSM106971, GSM106972); and CtIP-KD (GSM106974,
GSM106975) versus Luc-KD (GSM106976, GSM106977).
Luciferase reporter assay
ANG1 promoter constructs A (2821/+199), B (21799/+199), and C (23040/
+199), which regulate luciferase expression in pGL2 vector, were from Peter
Oettgen (Harvard Institutes of Medicine, MA) (Brown et al., 2004). Construct
C was subjected to site-directed mutagenesis (Stratagene) for deletion mu-
tations of ZBRK1 binding sites: C1 (D22600/22200), C2 (D21200/21800),
and C3 (D22600/21800); point mutations of a putative ZBRK1 site
(22310/22296): C-mt-Z; and for generating a fragment containing ZBRK1
binding sites (22600/21800): 3P-26-(wt/mt)-Z with respective primers
(Table S1). Correct changes were confirmed by sequencing and restriction
digestion.
MCF10A cells seeded at 53 105 cells/60mm plate were transfected with 3
mg of luciferase reporter and 0.5 mg of b-galactosidase plasmids using
Fugene6 prior to adenoviral RNAi infection. Luciferase and b-galactosidase
reporter activities were measured using a reporter assay kit (Promega).
EMSA
EMSA was performed as described (Zheng et al., 2000b). A g-32P-ATP-
labeled oligonucleotide probe (6000 cpm) harboring a ZBRK1 site (22310/
22296) in ANG1 promoter (wt-Z, 22319/22287) was incubated with 50 ng
of GST-ZBRK1-Zn protein purified from E. coli or 8 mg ofMCF10A nuclear ex-
tract of in 40 ml of DNA binding buffer containing 1 mg of poly(dI-dC) at room
temperature. For competition experiment, molar excess of an unlabeled
wild-type or mutant oligonucleotide was included. The sense oligonucleo-
tides used are from wild-type ZBRK1 site in ANG1 promoter (wt-Z): 50-ACAC
ACGTGGAGGAACAGATTTTTAACAGTCTC-30; a point mutant of the ZBRK1
site in ANG1 promoter (mt-Z): 50-ACACACGTGGTTGATTTGATTTTTAAC
AGTCTC-30; and a canonical ZBRK1 binding sequence (AP12) (Zheng
et al., 2000b): 50-GATCCACGGGACGCAGGTGTTTTGTGCCG-30 (ZBRK1
recognition motifs are shown in italics). The reaction was resolved on 5%
native polyacrylamide gel at 4ºC and autoradiographed.
DNA immunoprecipitation
DNA immunoprecipitation was performed as described (Zheng et al., 2000b).
A radiolabeled oligonucleotide of wt-Z, mt-Z, or AP12 was incubated with
50 mg of nuclear extract in 200 ml of DNA binding buffer containing 1 mg of
poly(dI-dC) at room temperature for 30 min. The protein-oligonucleotide
complex was precipitated by protein G-Sepharose beads loaded with
a respective antibody and resolved on 5% polyacrylamide gel followed by
autoradiography.
Immunoprecipitation
One microgram of antibody against HA (Ctrl), CtIP, BRCA1, or ZBRK1 was
added to 200 mg of preclarified MCF10A nuclear extract and incubated
at 4ºC overnight. Antibody-protein complex was precipitated by protein
G-Sepharose beads and washed with TEN buffer (10 mM Tris-HCl [pH
8.0], 0.25 mM EDTA, 50 mM NaCl). Immunoprecipitates were resolved on
8% SDS-PAGE and detected by Western analysis.22ChIP
ChIP assay was performed as described (Saccani et al., 2001) with a minor
modification. Chromatins from 1% formaldehyde-treated MCF10A cells
were sonicated to w500 bp fragments and immunoprecipitated with anti-
bodies against HA, ZBRK1, BRCA1, and CtIP at 4ºC overnight. Chromatin-
antibody complexes were washed with buffer 1 (0.1% SDS, 0.5% Triton
X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 8.0], 150 mM NaCl), buffer 2
(0.1% SDS, 2 mM EDTA, 20 mM Tris-HCl [pH 8.0], 500 mM NaCl) then TE
buffer (10 mM Tris-HCl [pH 8.0], 1 mM EDTA). After reversal of cross-linking,
immunoprecipitated chromatin was subjected to PCR reaction for a 300 bp
fragment (22400/22100) of ANG1 promoter around a ZBRK1 binding site
with respective primers (Table S1).
ANG1 retrovirus and siRNA
A full-length ANG1 cDNA, KIAA0003 clone (GenBank no. D13628) was from
Takahiro Nagase (Kazusa DNA Research Institute, Chiba, Japan) (Nomura
et al., 1994). A 1.7 kb coding sequence fragment was obtained by PCR reac-
tion with respective primers (Table S1) and cloned into pQCXIH vector (BD
Biosciences). GP2-293 packaging cells were transfected with pQCXIH/
ANG1 and pVSVG plasmids using Lipofectin, and retrovirus was harvested
in the conditioned medium. MCF10A cells were infected with retrovirus using
8 mg/ml polybrene, and the stable clones (MCF10A/ANG1) were selected
with 70 mg/ml Hygromycin B (Roche). Overexpression of ANG1 was con-
firmed by Western analysis using a rabbit anti-ANG1 antibody (1:500, Alpha
Diagnostic). ANG1 siRNA was synthesized against the target sequence:
50-AAGGCTTGGTTACTCGTCAAA-30 (Qiagen). MCF10A cells seeded at
5 3 105 cells/60 mm plate were transfected with 400 pmol of ANG1 or lucif-
erase siRNA for 24 hr using Oligofectamine (Invitrogen) prior to adenoviral
infection.
3D coculture
MCF10A cells (5 3 104) and HUVECs (5 3 104) were seeded together into
each well of a 8-well chamber slide coated with Matrigel and covered with
SFM supplemented with EGF and bFGF (Shekhar et al., 2000). Fluorescence
imaging was performed with Phase I/FITC filters on a Zeiss Axiovert 200M
equipped with Hamamatsu Photonics K.K. Deep Cooled Digital Camera
using Axiovision 4.4 software.
Mice, histology, and immunohistochemistry
Animal experiments were performed under federal guidelines and approved
by the Institutional Animal Care andUseCommittee at UCI. Mice with the p53
gene floxed at exons 5–6 (p53fp/fp) were generated as described (Lin et al.,
2004). Mice with the Brca1 gene floxed at exon 11 (Brca1f11/f11) were from
Chu-Xia Deng (NIH) (Xu et al., 1999). Both strains were crossed to obtain
Brca1f11/f11;p53fp/fp mice. p53fp/fp or Brca1f11/f11;p53fp/fp mice were
crossed with Wap-Cre mice and genotyped to obtain the p53D5–6/D5–6 or
Brca1D11/D11; p53D5–6/D5–6 strain, respectively. Dissected mouse mammary
tumors were fixed in 4% paraformaldehyde overnight. Sections (4–5 mm)
were deparaffinized, hydrated, and digested in 0.05% trypsin at 37ºC. After
being blocked with 3%H2O2 and nonimmune horse serum, sections were in-
cubated at room temperature with a rabbit anti-mouse CD31 antibody and
link antibodies, followed by peroxidase-conjugated streptavidin complex
and diaminobenzidine tetrahydroxychloride solution as the peroxidase
substrate (Vector Laboratories). The sections were counterstained with
hematoxylin. Photomicrographs were taken with Zeiss Axioplan 2 Imaging
platform and AxioVision 4.4 Software. Six to eight nonoverlapping images
for each tumor sample were captured at 2003 magnification and analyzed
for vascular pathology using AxioVion 4.4. Briefly, each blood vessel was
marked and the number within a field of 2003 magnification was counted.
The lumen of an individual vessel was outlined to compute the area, and
the total luminal area of the field was determined. The mean luminal area of
a single vessel within a field was calculated and then averaged among
multiple fields for each tumor sample. The statistical significance was evalu-
ated by Student’s t test using MS Excel XP. High-magnification images were
captured at 10003 magnification.
Supplemental data
The Supplemental Data include one supplemental figure and one supple-
mental table and can be found with this article online at http://www.
cancercell.org/cgi/content/full/10/1/13/DC1/.CANCER CELL JULY 2006
A R T I C L EAcknowledgments
We thank Dr. Peter Oettgen (Harvard Institutes of Medicine, MA) forANG1 re-
porter constructs; Dr. Christopher Hughes (UCI) for HUVECs; Dr. Takahiro
Nagase (Kazusa DNA Research Institute, Chiba, Japan) for the KIAA0003
clone; Dr. Chu-Xia Deng (NIH) for Brca1-floxed mice; and Eric Wang, Chris-
topher Smith, and Suh-Chin J. Lin for their assistance. This work was sup-
ported by grants from the National Institutes of Health (RO1 CA94170 to
W.-H.L.; R37 CA049649 to E.Y.-H.P.L.), a predoctoral fellowship from the
Department of Defense (W81XWH-05-1-0322 to S.F.), and a physician scien-
tist award from the National Health Research Institute in Taiwan to Y.-M.J.
Received: December 1, 2005
Revised: March 18, 2006
Accepted: May 2, 2006
Published: July 17, 2006
References
Brown, C., Gaspar, J., Pettit, A., Lee, R., Gu, X., Wang, H., Manning, C.,
Voland, C., Goldring, S.R., Goldring, M.B., et al. (2004). ESE-1 is a novel
transcriptional mediator of angiopoietin-1 expression in the setting of inflam-
mation. J. Biol. Chem. 279, 12794–12803.
Caine, G.J., Blann, A.D., Stonelake, P.S., Ryan, P., and Lip, G.Y.H. (2003).
Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate can-
cer: a comparison with VEGF and Flt-1. Eur. J. Clin. Invest. 33, 883–890.
Chen, Y., Chen, C.F., Riley, D.J., Allred, D.C., Chen, P.L., Von Hoff, D.,
Osborne, C.K., and Lee, W.H. (1995). Aberrant subcellular localization of
BRCA1 in breast cancer. Science 270, 789–791.
Chen, Y., Farmer, A.A., Chen, C.F., Jones, D.C., Chen, P.L., and Lee, W.H.
(1996). BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and
phosphorylated in a cell cycle-dependent manner. Cancer Res. 56, 3168–
3172.
Chen, P.L., Liu, F., Cai, S., Lin, X., Li, A., Chen, Y., Gu, B., Lee, E.-H.P., and
Lee, W.-H. (2005). Inactivation of CtIP leads to early embryonic lethality me-
diated by G1 restraint and to tumorigenesis by haploid insufficiency. Mol.
Cell. Biol. 25, 3535–3542.
Chinnadurai, G. (2006). CtIP, a candidate tumor susceptibility gene is a team
player with luminaries. Biochim. Biophys. Acta 1765, 67–73.
Couch, F.J., DeShano, M.L., Blackwood, M.A., Calzone, K., Stopfer, J.,
Campeau, L., Ganguly, A., Rebbeck, T., andWeber, B.L. (1997). BRCA1 mu-
tations in women attending clinics that evaluate the risk of breast cancer.
N. Engl. J. Med. 336, 1409–1415.
Cullmann, G., Fien, K., Kobayashi, R., and Stillman, B. (1995). Characteriza-
tion of the five replication factor C genes of Saccharomyces cerevisiae. Mol.
Cell. Biol. 15, 4661–4671.
Davila, M., Frost, A.R., Grizzle, W.E., and Chakrabarti, R. (2003). LIM kinase 1
is essential for the invasive growth of prostate epithelial cells: implications in
prostate cancer. J. Biol. Chem. 278, 36868–36875.
Debnath, J., Muthuswamy, S.K., and Brugge, J.S. (2003). Morphogenesis
and oncogenesis of MCF-10A mammary epithelial acini grown in three-
dimensional basement membrane cultures. Methods 30, 256–268.
Easton, D.F., Bishop, D.T., Ford, D., and Crockford, G.P. (1993). Genetic link-
age analysis in familial breast and ovarian cancer: results from 214 families.
The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 52, 678–701.
Foulkes,W.D., Metcalfe, K., Hanna,W., Lynch, H.T., Ghadirian, P., Tunng, N.,
Olopade, O., Weber, B.L., McLennan, J., Olivotto, I.A., et al. (2003). Disrup-
tion of the expected positive correlation between breast tumor size and
lymph node status in BRCA1-related breast carcinoma. Cancer 98, 1569–
1577.
Furuta, S., Jiang, X., Gu, B., Cheng, E., Chen, P.L., and Lee, W.H. (2005).
Depletion of BRCA1 impairs differentiation but enhances proliferation of
mammary epithelial cells. Proc. Natl. Acad. Sci. USA 102, 9176–9181.CANCER CELL JULY 2006Fusco, C., Reymond, A., and Zervos, A.S. (1998). Molecular cloning and
characterization of a novel retinoblastoma-binding protein. Genomics 51,
351–358.
Goffin, J.R., Straume, O., Chappuis, P.O., Brunet, J.-S., Be´gin, L.R., Hamel,
N., Wong, N., Akslen, L.A., and Foulkes, W.D. (2003). Glomeruloid microvas-
cular proliferation is associated with p53 expression, germline BRCA1 muta-
tions and an adverse outcome following breast cancer. Br. J. Cancer 89,
1031–1034.
Hakem, R., de la Pompa, J.L., Sirard, C., Mo, R., Woo, M., Hakem, A., Wake-
ham, A., Potter, J., Reitmair, A., Billia, F., et al. (1996). The tumor suppressor
gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell
85, 1009–1023.
Hashizume, R., Fukuda, M., Maeda, I., Nishikawa, H., Oyake, D., Yabuki, Y.,
Ogata, H., and Ohta, T. (2001). The RING heterodimer BRCA1-BARD1 is
a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol.
Chem. 276, 14537–14540.
Hayes, A.J., Huang, W.Q., Mallah, J., Yang, D., Lippman, M.E., and Li, L.Y.
(1999). Angiopoietin-1 and its receptor Tie-2 participate in the regulation of
capillary-like tubule formation and survival of endothelial cells. Microvasc.
Res. 58, 224–237.
He, T.-C., Zhou, S., da Costa, L.T., Yu, J., Kinzler, K.W., and Vogelstein, B.
(1998). A simplified system for generating recombinant adenoviruses. Proc.
Natl. Acad. Sci. USA 95, 2509–2514.
Imura, S., Miyake, H., Izumi, K., Iashiro, S., and Uehara, H. (2004). Correlation
of vascular endothelial cell proliferation with microvessel density and expres-
sion of vascular endothelial growth factor and basic fibroblast growth factor
in hepatocellular carcinoma. J. Med. Invest. 51, 202–209.
Kwak, H.J., So, J.N., Lee, S.J., Kim, I., and Koh, G.Y. (1999). Angiopoietin-1 is
an apoptosis survival factor for endothelial cells. FEBS Lett. 448, 249–253.
Lane, T.F., Deng, C., Elson, A., Lyu, M.S., Kozak, C.A., and Leder, P. (1995).
Expression of Brca1 is associated with terminal differentiation of ectoder-
mally and mesodermally derived tissues in mice. Genes Dev. 9, 2712–2722.
Li, S., Chen, P.L., Subramanian, T., Chinnadurai, G., Tomlinson, G., Osborne,
C.K., Sharp, Z.D., and Lee,W.-H. (1999). Binding of CtIP to the BRCT repeats
of BRCA1 involved in the transcription regulation of p21 is disrupted upon
DNA damage. J. Biol. Chem. 274, 11334–11338.
Li, S., Ting, N.S.Y., Zheng, L., Chen, P.L., Zlv, Y., Shlloh, Y., Lee, E.-H.P., and
Lee, W.-H. (2001). Functional link of BRCA1 and ataxia telangiectasia gene
product in DNA damage response. Nature 406, 210–215.
Lin, S.C., Lee, K.F., Nikitin, A.Y., Hilsenbeck, S.G., Cardiff, R.D., Li, A., Kang,
K.W., Frank, S.A., Lee, W.-H., and Lee, E.Y. (2004). Somatic mutation of p53
leads to estrogen receptor alpha-positive and -negative mouse mammary
tumors with high frequency of metastasis. Cancer Res. 64, 3525–3532.
Liu, C.Y., Flesken-Nikitin, A., Li, S., Zeng, Y., and Lee, W.H. (1996). Inactiva-
tion of themouse Brca1 gene leads to failure in themorphogenesis of the egg
cylinder in early postimplantation development. Genes Dev. 10, 1835–1843.
Machein, M.R., Knedla, A., Knoth, R., Wagner, S., Neuschl, E., and Plate,
K.H. (2004). Angiopoietin-1 promotes tumor angiogenesis in a rat glioma
model. Am. J. Pathol. 165, 1557–1570.
Marquis, S.T., Rajan, J.V., Wynshaw-Boris, A., Xu, J., Yin, G.Y., Abel, K.J.,
Weber, B.L., and Chodosh, L.A. (1995). The developmental pattern of
Brca1 expression implies a role in differentiation of the breast and other
tissues. Nat. Genet. 11, 17–26.
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P.A., Harshman, K., Tav-
tigian, S., Liu, Q., Cochran, C., Bennett, L.M., and Ding, W. (1994). A strong
candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Science 266, 66–71.
Nomura, N., Miyajima, N., Sazuka, T., Tanaka, A., Kawarabayasi, Y., Sato, S.,
Nagase, T., Seki, N., Ishikawa, K., and Tabata, S. (1994). Prediction of the
coding sequences of unidentified human genes. DNA Res. 1, 27–35.
Saccani, S., Pantano, S., and Natoli, G. (2001). Twowaves of nuclear factor B
recruitment to target promoters. J. Exp. Med. 193, 1351–1359.
Schaeper, U., Subramanian, T., Lim, L., Boyd, J.M., and Chinnadurai, G.
(1998). Interaction between a cellular protein that binds to the C-terminal23
A R T I C L Eregion of adenovirus E1A (CtBP) and a novel cellular protein is disrupted by
E1A through a conserved PLDLS motif. J. Biol. Chem. 273, 8549–8552.
Shekhar, M.P.V., Werdell, J., and Tait, L. (2000). Interaction with endothelial
cells is a prerequisite for branching ductal-alveolar morphogenesis and hy-
perplasia of preneoplastic human breast epithelial cells: regulation by estro-
gen. Cancer Res. 60, 439–449.
Stoppa-Lyonnet, D., Ansquer, Y., Dreyfus, H., Gautier, C., Gauthier-Villars,
M., Bourstyn, E., Clough, K.B., Magdelenat, H., Pouillart, P., Vincent-Salo-
mon, A., et al. (2000). Familial invasive breast cancers: worse outcome
related to BRCA1 mutations. J. Clin. Oncol. 18, 4053–4059.
Sui, G., Soohoo, C., Affar el, B., Gay, F., Shi, Y., Forrester, W.C., and Shi, Y.
(2002). A DNA vector-based RNAi technology to suppress gene expression in
mammalian cells. Proc. Natl. Acad. Sci. USA 99, 5515–5520.
Suri, C., Jones, P.F., Patan, S., Bartunkova, S., Maisonpierre, P.C., Davis, S.,
Sato, T.N., and Yancopoulos, G.D. (1996). Requisite role of angiopoietin-1,
a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87,
1171–1180.
Takakura, N., Watanabe, T., Suenobu, S., Yamada, Y., Noda, T., Ito, Y., Sa-
take, M., and Suda, T. (2000). A role for hematopoietic stem cells in promot-
ing angiogenesis. Cell 102, 199–209.
Tan, W., Zheng, L., Lee, W.H., and Boyer, T.G. (2004). Functional dissection
of transcription factor ZBRK1 reveals zinc fingers with dual roles in DNA-
binding and BRCA1-dependent transcriptional repression. J. Biol. Chem.
279, 6576–6587.
Tessari, M.A., Gostissa, M., Altamura, S., Sgarra, R., Rustighi, A., Salvagno,
C., Caretti, G., Imbriano, C., Mantovani, R., Del Sal, G., et al. (2003). Tran-
scriptional activation of the cyclin A gene by the architectural transcription
factor HMGA2. Mol. Cell. Biol. 23, 9104–9116.
Thompson, M.E., Jensen, R.A., Obermiller, P.S., Page, D.L., and Holt, J.T.
(1995). Decreased expression of BRCA1 accelerates growth and is often
present during sporadic breast cancer progression. Nat. Genet. 9, 444–450.24Thurston, G., Wang, Q., Baffert, F., Rudge, J., Papadopoulos, N., Jean-Guil-
laume, D., Wiegand, S., Yancopoulos, G.D., and McDonald, D.M. (2005).
Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting,
during a critical developmental period. Development 132, 3317–3326.
Xu, X., Wagner, K.U., Larson, D., Weaver, Z., Li, C., Ried, T., Hennighausen,
L., Wynshaw-Boris, A., and Deng, C.X. (1999). Conditional mutation of Brca1
in mammary epithelial cells results in blunted ductal morphogenesis and
tumour formation. Nat. Genet. 22, 37–43.
Yu, X., and Chen, J. (2004). DNA damage-induced cell cycle checkpoint
control requires CtIP, a phosphorylation-dependent binding partner of
BRCA1 C-terminal domains. Mol. Cell. Biol. 24, 9478–9486.
Yu, X., Wu, L.C., Bowcock, A.M., Aronheim, A., and Baer, R. (1998). The
C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein
implicated in the CtBP pathway of transcriptional repression. J. Biol.
Chem. 273, 25388–25392.
Zheng, L., Li, S., Boyer, T.G., and Lee, W.-H. (2000a). Lessons learned from
BRCA1 and BRCA2. Oncogene 19, 6159–6175.
Zheng, L., Pan, H., Li, S., Flesken-Nikitin, A., Chen, P.L., Boyer, T.G., and
Lee, W.H. (2000b). Sequence-specific transcriptional corepressor function
for BRCA1 through a novel zinc finger protein, ZBRK1. Mol. Cell 6, 757–768.
Zhong, Q., Chen, C.F., Li, S., Chen, Y., Wang, C.C., Xiao, J., Chen, P.L.,
Sharp, Z.D., and Lee, W.H. (1999). Association of BRCA1 with the hRad50-
hMre11-p95complex and theDNAdamage response. Science285, 747–750.
Accession numbers
Microarray data are available at Gene Expression Omnibus (GEO; http://
www.ncbi.nlm.nih.gov/geo/) with the following accession numbers:
BRCA1-KD (GSM106933, GSM106968) versus Luc-KD (GSM106971,
GSM106972); and CtIP-KD (GSM106974, GSM106975) versus Luc-KD
(GSM106976, GSM106977).CANCER CELL JULY 2006
